Business Description
Abbisko Cayman Limited is a Shanghai-based pharmaceutical company founded in 2016 that discovers and develops targeted drug treatments for patients in China and the European Union. Its most advanced medicines include Pimicotinib, a treatment for rare joint tumors nearing commercial approval, and Irpagratinib, a liver cancer therapy in late-stage trials. The company maintains a broad pipeline of experimental drugs addressing a range of conditions, from lung and gastric cancers to obesity and respiratory disease, at various stages of research and clinical testing.
